Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.

Evangelos K OikonomouMarc A SuchardDarren K McGuireRohan Khera

Published in: Diabetes care (2022)

We present an evidence-based, machine learning-guided algorithm to personalize the prescription of SGLT2 inhibitors for patients with type 2 diabetes for ASCVD effects.

Keyphrases

machine learning
type diabetes
artificial intelligence
deep learning
big data
glycemic control
cardiovascular disease
insulin resistance